Teva launches Stelara biosimilar at 85% discount as wider field emerges

Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to Johnson & Johnson's blockbuster immunosuppressive biologic Stelara, offering a steep discount. The Stelara biosimilar field is shaping up to be a ...

Related Posts

Neumora replaces CEO with ex-chief Berns after trial fa...

Feb 13, 2025  0

Updates from Washington; A trio of Big Pharma deals; Wh...

Feb 15, 2025  0

States sue Trump administration over billions in NIH in...

Feb 10, 2025  0

Comments

Name

Email

Comment

Post Comment